For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
According to our LPI (LP Information) latest study, the global Artificial Pancreas Devices Systems market size was valued at US$ 87 million in 2023. With growing demand in downstream market, the Artificial Pancreas Devices Systems is forecast to a readjusted size of US$ 199.2 million by 2030 with a CAGR of 12.6% during review period.
The research report highlights the growth potential of the global Artificial Pancreas Devices Systems market. Artificial Pancreas Devices Systems are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Artificial Pancreas Devices Systems. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Artificial Pancreas Devices Systems market.
The Artificial Pancreas Device System is a system of devices that closely mimics the glucose regulating function of a healthy pancreas.
Most Artificial Pancreas Device Systems consists of three types of devices already familiar to many people with diabetes: a continuous glucose monitoring system (CGM) and an insulin infusion pump. A blood glucose device (such as a glucose meter) is used to calibrate the CGM.
A computer-controlled algorithm connects the CGM and insulin infusion pump to allow continuous communication between the two devices. Sometimes an artificial pancreas device system is referred to as a "closed-loop" system, an "automated insulin delivery" system, or an "autonomous system for glycemic control."
An Artificial Pancreas Device System will not only monitors glucose levels in the body but also automatically adjusts the delivery of insulin to reduce high blood glucose levels (hyperglycemia) and minimize the incidence of low blood glucose (hypoglycemia) with little or no input from the patient.
Medtronic monopolizes the global Artificial Pancreas Devices Systems market, holding a share about 100%.
North America is the largest market, with a share about 60%, followed by Europe, have a share about 30 percent.
In terms of product, Threshold Suspended Device Systems is the largest segment, with a share over 60%. And in terms of application, the largest application is Hospitals
, followed by Clinics.
Key Features:
The report on Artificial Pancreas Devices Systems market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Artificial Pancreas Devices Systems market. It may include historical data, market Segmentation by Type (e.g., Threshold Suspended Device Systems, Hybrid Closed-loop APDS), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Artificial Pancreas Devices Systems market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Artificial Pancreas Devices Systems market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Artificial Pancreas Devices Systems industry. This include advancements in Artificial Pancreas Devices Systems technology, Artificial Pancreas Devices Systems new entrants, Artificial Pancreas Devices Systems new investment, and other innovations that are shaping the future of Artificial Pancreas Devices Systems.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Artificial Pancreas Devices Systems market. It includes factors influencing customer ' purchasing decisions, preferences for Artificial Pancreas Devices Systems product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Artificial Pancreas Devices Systems market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Artificial Pancreas Devices Systems market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Artificial Pancreas Devices Systems market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Artificial Pancreas Devices Systems industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Artificial Pancreas Devices Systems market.
Market Segmentation:
Artificial Pancreas Devices Systems market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
- Threshold Suspended Device Systems
- Hybrid Closed-loop APDS
- Other Systems
Segmentation by application
- Hospitals
- Clinics
This report also splits the market by region:
- Americas
- - United States
- - Canada
- - Mexico
- - Brazil
- APAC
- - China
- - Japan
- - Korea
- - Southeast Asia
- - India
- - Australia
- Europe
- - Germany
- - France
- - UK
- - Italy
- - Russia
- Middle East & Africa
- - Egypt
- - South Africa
- - Israel
- - Turkey
- - GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
- Medtronic
- Bigfoot Biomedical
- Beta Bionics
- Admetsys
- Insulet
- Tandem Diabetes Care
- Defymed
Key Questions Addressed in this Report
What is the 10-year outlook for the global Artificial Pancreas Devices Systems market?
What factors are driving Artificial Pancreas Devices Systems market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Artificial Pancreas Devices Systems market opportunities vary by end market size?
How does Artificial Pancreas Devices Systems break out type, application?